Deliver logo
Agenda
VISONARY KEYNOTE SESSIONS

KEYTRUDA®(pembrolizumab) for the Treatment of Multiple Types of Cancer – Utilize Asia and China as an important source of Innovation
Dr. Roger D. Dansey,Sr. Vice President, Clinical Research –Late Stage Oncology, Global Clinical Development –Oncology, Merck & Co. Inc.

Advancing Immune Oncology in China– How best to address important unmet needs in China with an integrated global and local clinical research strategy
Dr. Katrin Rupalla,Head of Development, BMS R&D China

Growth in Quality of Innovation – A Perspective about Drug Discovery in China
Abstract: This talk will highlight the key components of the vibrant innovation ecosystem of drug discovery and development in China. Specifically, examples of the drug discovery projects at Roche Innovation Center Shanghai will be covered to showcase how MNCs in China move exciting first-in-class/best-in-class potential programs forward through seamless internal and external collaboration. Finally, Roche’s external collaboration strategy and efforts in China will be summarized at a high level.
-- Promoting China Innovation – Innovative Drug Discovery Highlights
-- Lay foundations for effective partnership with top CROs, Biotech and Academia
-- Opportunities for Medicinal Chemistry Outsourcing in China
-- External innovation model of Roche in China
Dr. Hong Shen,Head of Medicinal Chemistry and Head of External Innovation, Therapeutic Modalities, Roche Innovation Center Shanghai ( RICS )

Accelerating Drug Discovery: Integration of Chem-Informatics, Drug-like Reagent collections and Screening Automation to Improve Success Rate
Abstract:This talk will illustrate the principles of an emerging capability with the potential for being truly transformational in our efforts to improve efficiency in drug discovery. Recent advances in several discrete scientific and technological areas have enhanced our ability to mine, fuse and analyze large data sets, model relevant drug-like chemical space, and enhance our ability to execute on medicinal chemistry and in vitro pharmacology. Harnessing these aptitudes, we have developed an integrated “design cycle”which is an iterative, data driven process enabled by the following components:
-- A parallel design tool enabling virtual enumeration and in silico evaluation of theoretical candidates (ALDaS, Automated Library Design and Synthesis; Drug-like Reagent collection)
-- Visualization and sampling from bio- and chemo-similar subgroups of this virtual space (SOM analysis)
-- Rapid, parallel nano-scale pre-screening of reaction conditions
-- Enabled parallel synthesis of a small subset of the most relevant candidates (PMC, Parallel Medicinal Chemistry)
-- Facile generation and analysis of biological data, in both standard LO mode and microscale, non-purified, enrichment mode
Dr. Philippe G. Nantermet, Principal Scientist, Director, External Discovery Chemistry, Merck & Co., Inc

PharmaEssentia P1101 Program Highlight: Global Co-Development & Partnership
-- Share resources to amplify mutual interests and accelerate success
-- Partnership agreement that defines the important terms of relationship
--Strategic & Tactical Integration
Dr. Ko-Chung Lin,Founder and Chief Executive Officer, PharmaEssentia Corp

TransCelerate BioPharma Mission in China -- Opportunities for Innovation -- Perceiving the Role and Importance of China for Global Drug Development
Dr. QingAn Jiao,Senior Director, Head of Global Clinical Operations ( GCO ) China,Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd /Country Lead for China, TransCelerate BioPharma Inc.

Open Innovation Model for University-Industrial Strategic Partnership at Peking University
Prof. Dongmin Chen,Dean, School of Innovation and Entrepreneurship | Director, Office of Science & Technology Development Dongxu Chair Professor, Advanced Interdisciplinary Studies & School of Innovation and Entrepreneurship, Peking University

Novel Paradigms for Academic/Industry Partnership
Dr. Ferran Prat,Sr. Vice President, Research Administration and Industry Relations,MD Anderson Cancer Center

INTERACTIVE ROUNDTABLE DISCUSSIONS

Revolution in Future Cancer Treatment -- How Will it Scale over the Next 10 Years
-- Evaluating the Current State of the Next Generation Immuno-Oncology Therapeutics
-- What New Immuno-oncology Modalities Have the highest Promise: Are TCR Therapies ready for Prime Time
-- Development of IO Combos from the Provider Perspective – How to Prioritize
-- Cell Therapy at the Point-of-Care: Will Cell Therapy Follow the Same Model as Radiation Therapy or Laboratory Medicine

Moderator:
Dr. Ferran Prat,Sr. Vice President, Research Administration and Industry Relations,MD Anderson Cancer Center

Panelists:
Dr. Roger D. Dansey,Sr. Vice President, Clinical Research –Late Stage Oncology, Global Clinical Development –Oncology, Merck & Co. Inc.
Dr. Katrin Rupalla,Head of Development, BMS R&D China
Dr. Xiang Yang Zhu, CEO, Huabo Biopharma (Shanghai) Co., Ltd
Dr. Zhenping Zhu, President of Research and Development and Chief Scientific Officer, 3SBio Inc.
Dr.Ko-Chung Lin,Founder and Chief Executive Officer, PharmaEssentia Corp
Dr. Michael Chen,Head of External Innovation China, Biopharma | Global Research and Development | External Innovation, Merck

Medicinal Chemistry Outsourcing in China – Lessons Learned

Moderator:
Dr. Joseph L. Duffy,Executive Director, Head of External Discovery Chemistry, Merck

Panelists:
Dr. Tobias Gabriel, Global Head of External Drug Discovery at Global Discovery Chemistry, Novartis Institutes for BioMedical Research
Dr. Changyou Zhou, Senior Vice President, Executive Head of Chemistry, BeiGene
Dr. Wenge Zhong,Scientific Director, Head of Medicinal Chemistry, Amgen Asia R&D Center
Dr. Hong Shen,Head of Medicinal Chemistry and Head of External Innovation, Therapeutic Modalities,Roche Innovation Center Shanghai ( RICS )
Dr. Zhao-Kui Wan, Head of Chemistry, China R&D and Medical Affairs,Janssen ( China ) Research & Development Center, A Division of Johnson & Johnson ( China ) Investment Ltd.
Prof. Yun He,Dean, School of Pharmaceutical Sciences, Innovative Drug Research Center,Chongqing University

R&D Leaders Roundtable:Pharma R&D Innovative Collaboration and Promoting China Innovation
Abstract: This featured R&D Leaders roundtable discussion will explore the evolving future of innovative R&D in China: We have invited the leaders in Global/Regional R&D Executives to share their vision and experience in promoting drug discover innovation in Asia

Moderator:
Dr. Tobias Gabriel, Global Head of External Drug Discovery at Global Discovery Chemistry, Novartis Institutes for BioMedical Research

Panel Speakers:
Dr. Per Cantor, Senior Vice President, Global Clinical & Non-Clinical R&D International PharmaScience Center, FERRING
Dr. Joe Zhang, Head of Preclinical R&D, Simcere Pharmaceuticals
Dr. Xiang Yang Zhu, CEO, Huabo Biopharma (Shanghai) Co., Ltd
Dr. Min Wu,Executive Director, Search and Evaluation, Asia Pacific Innovation Hub,MSD
Dr. Ying-jie Wu,Associate Director, Asia & Emerging Markets,Roche Partnering
Dr. Michael Chen ,Head of External Innovation China, Biopharma | Global Research and Development | External Innovation, Merck

Asia Pharma R&D Leaders Summit 2018  |  Telephone: +86 21 6172 6970  |  E-mail: kevin.tan@deliver-consulting.com
© 2017 Asia Pharma R&D Leaders Summit 2018- All rights reserved